Xeljanz/xeljanz Xr (tofacitinib) – Risk Of Major Adverse Cardiovascular Events, Malignancy, Thrombosis And Infection
Recall Summary Xeljanz and Xeljanz XR (tofacitinib) are being recalled in Canada due to new safety information showing risks of serious heart problems, cancer, blood clots, and infections. The medication is used to treat conditions like rheumatoid arthritis and is distributed across Canada. This recall reflects updated safety data about potential adverse effects associated with the drug.
- Product
- XELJANZ/XELJANZ XR (tofacitinib)
- Reason
- New safety information - Product safety
- Category
- drug recall
- Country
- Canada
- Agency
- HC-DRUGS
- Recall date
- 2022-01-12
- Status
- Ongoing
- Distribution
- Canada-wide
Official recall notice from HC-DRUGS
Recall details on Nibble Recalls: https://trynibble.app/recalls/caa5dd5c-ff69-478e-bd98-e3cfc11779b0